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Precis: Fatigue and role functioning deteriorated temporarily during 
radiotherapy. Emotional functioning scales showed an improvement during 
observation period. 
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Abstract 
Background:  The aim of this study was to describe prospectively Quality of Life 
(QOL) before and after radiotherapy for prostate cancer.  
Methods: Forty-three patients with T1-T3 prostate cancer treated with conformal 
external beam radiation therapy were randomized either to the complete QOL 
questionnaire EORTC-QlQ-C30 or the SF-36 at baseline, 3 and 6 weeks after 
initial treatment, and 6 weeks and 5 months after completion of radiotherapy. 
The measures were self-reported patient QOL and values are given as mean SEM. 
Changes in QOL are described from baseline to the end of treatment in both 
questionnaire groups.  
Results: Emotional role functioning as measured with the SF-36 questionnaire 
significantly improved from 68.29.9 at baseline to 93.35.2 at the end of 
therapy (p=0.02). The EORTC QLQ-C30 questionnaire revealed consistent values of 
emotional functioning during treatment (72.75.9 at baseline) but showed a 
significant improvement 6 weeks after therapy (89.04.4) (p=0.01). Role 
functioning deteriorated from 80.16.5 at baseline to 62.58.8 at the end of 
radiotherapy (p=0.02). Symptoms of fatigue were shown to significantly increase 
from 26.96.0 at baseline to 37.77.6 at the end of therapy (p=0.02). No 
significant changes in the other dimensions were observed in either 
questionnaire.  
Conclusions: After radiotherapy for prostate cancer, a temporary deterioration 
of fatigue and role functioning as measured with the EORTC QLQ-C-30 was 
measured. Despite physical deterioration, we observed an improvement of 
emotional functioning scores with both questionnaires. This might be due to 
psychological adaptation and coping.  
 
Key words: quality of life, radiotherapy, prostate cancer, fatigue, role 
functioning, emotional functioning 
 
 
                     Janda et al., page 4 
Background 
Prostate carcinoma is the most commonly registered malignancy in men in the USA, 
with an estimated 180.400 new cases in the year 2000 (1). Early detection has 
contributed to a peak in incidence of the disease between 1989 and 1992 (1,2). 
It is widely believed that the incidence of prostate cancer has not increased; 
merely the incidence of prostate cancer detection has increased since the advent 
of Prostate Specific Antigen (PSA). However, the actual benefit of early 
detection on prostate cancer mortality is still controversially discussed (2). 
More men than ever before are confronted with the diagnosis of cancer and the 
physical and psychological implications of the disease and treatment at a 
younger age of life. Screening programs themselves have been reported to cause 
psychological symptoms such as anxiety, worry and tense expectation of test 
results (3,4). Individuals faced with the diagnosis of cancer have been shown to 
demonstrate significant changes in psychosocial wellbeing such as trust in the 
functioning of one's body, fear of pain, fear of dying, worry about the 
disruption of normal life, worry about the implications of cancer treatment, 
etc. (5-8).  
Radical prostatectomy and radiotherapy remain standard treatment modalities. 
Both procedures are reported to be similar in terms of survival, but both also 
have different side effects, which impair the individual's wellbeing (9,10). 
Quality of life (QOL) is a multidimensional construct (11), which gives the 
patient the possibility to describe his subjective feelings about his personal 
physical, psychological and social wellbeing at a specific time point (11). QOL 
is measured with questionnaires, the majority of which include subscales for 
these dimensions and substantiate the patients' descriptions with questions that 
are easy to understand. Cella (12) reviewed the literature for existing QOL 
measurements and described seven dimensions which are sufficiently distinct to 
warrant separate listing: physical concerns (symptoms, pain), functional ability 
(activity), family well-being, emotional well-being, treatment satisfaction 
(including financial concerns), sexuality/intimacy (including body image), 
social functioning. Some results from the literature support the suggestion that 
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quality of life could carry independent prognostic information (13,14). 
Additionally, knowledge of the quality of life helps physicians to inform their 
patients more comprehensively (4,8,15,16).  
Participating in the decision-making process in regard of treatment has been 
shown to have a positive impact on coping with the disease (17). Healthcare 
professionals often over- or underestimate a patient's subjective morbidity and 
QOL (7,18-21). The type, frequency and severity of treatment-related side 
effects for prostate cancer have been described in several studies (7,9,22,23). 
However, prospective data concerning the impact of these side effects on the 
quality of life are still limited (6,24,25,26). It was hypothesized that at 
least some quality of life subscales change during radiotherapy. In the present 
study we therefore evaluated quality of life before, during and six months after 
radiotherapy for prostate cancer prospectively. 
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Methods 
Between May 1997 and September 1997, all patients who underwent conformal 
external beam radiation therapy for prostate cancer were asked to participate in 
this prospective trial.  
Patients were included if they had histologically proven prostate cancer stage 
T1-T3, were able to understand and read German well enough to answer the 
questionnaires, were between 50 and 85 years of age and had given written 
informed consent. Patients were excluded if they had any kind of distant 
metastases, language difficulties, suffered acutely from other illnesses such as 
cardiovascular disease that could impair their quality of life, or refused to 
participate. 
All patients received CT-based 3-D planned conformal radiotherapy to the 
prostate ( seminal vesicles) or the prostate bed, in accordance with the 
recommendation of the ICRU Report 50. The prescription dose was 66 Gray (Gy) to 
the ICRU reference point, 2 Gy per fraction, using a four-field box technique. 
In two patients pelvic irradiation up to 46 Gy was performed due to positive 
iliac lymph nodes. Twenty patients received adjuvant hormonal treatment during 
the study period, in 6 patients orchiectomy was performed before radiotherapy, 
and 16 patients received no hormonal treatment during the study period. 
All patients were randomised either to the complete the German version Medical 
Outcomes Study Group Short Form Health Survey (SF-36) (27) or the German version 
QOL European Organisation for Research and Treatment Quality of Life 
Questionnaire (EORTC-QlQ-C30) (28). Both questionnaires are validated and widely 
used and described in detail elsewhere (27, 28). The QlQ-C30 was developed to 
describe the difficulties and problems of cancer patients. The SF-36 is a more 
generic measure (29), which is used for various diseases including cancer. Since 
localized prostate cancer does not affect general wellbeing in many cases, it 
was of interest to determine which of these questionnaires would be more useful 
to describe the patients' subjective feelings. 
The questionnaire SF-36 covers eight dimensions of health-related quality of 
life: physical functioning, social functioning, pain, emotional well-being, 
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energy/fatigue, general health perceptions, role limitations due to physical 
problems, and role limitations due to emotional problems. All scores have been 
transformed using the RAND scoring method (27), resulting in scores between 0 
and 100, with higher scores representing better QOL. 
The questionnaire QLQ-C 30 consists of 30 items. It incorporates five functional 
scales (physical, role, cognitive, emotional, social), three symptom scales 
(fatigue, pain, and nausea and vomiting), a global health status/QOL scale and a 
number of single-item scales (28). All scores have been transferred to 
continuous scales ranging from 0 to 100, with higher scores representing better 
QOL except for the symptom scales, where higher scores indicate more or more 
severe symptoms. 
Seven scales that are included in both questionnaires (Table 1) were analyzed 
for the present study. The patients completed the questionnaires at five time 
points. Pretreatment/baseline was defined as the period within one week before 
radiation therapy was started. All patients had knowledge of their diagnosis for 
at least 3 to 5 weeks prior to their first admission of the radiotherapy 
department. All patients had passed clinical investigation and received 
brochures about radiotherapy for prostate cancer at least 2 weeks prior to first 
treatment from their radiotherapist. At this time patients were asked to 
participate in this QOL study by their physicians. They received a study 
information sheet and informed consent was obtained.  
Subsequent timepoints were calculated as following: the middle of radiotherapy 
comprised day 21 to 28 of radiotherapy, and the end of radiotherapy extended 
from day 42 to 47 of radiotherapy. The first follow-up was performed at 12 to 14 
weeks after baseline, the second follow up 30 to 32 weeks after baseline. The 
timepoints of follow up were coordinated with the clinical useful follow up 
timepoints to reduce the burden for the patients. 
Questionnaires were mailed to patients who had been missed at follow up. 
A change of ten to fifteen score points on a zero-to-hundred scale has been 
interpreted as a meaningful change in quality of life scores. Since patients can 
serve as their own controls in longitudinal settings and because of high test-
retest reliabilities in both questionnaires, a total of 25 to 30 patients are 
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required to detect a ten- to fifteen-point change with a power of 80 to 90% 
(30). 
Results are based on the data of 41 patients who completed the questionnaires at 
at least three time points: baseline, the middle of radiotherapy and the end of 
radiotherapy. Fifty-four patients who met the selection criteria were asked to 
participate in the study. Eleven out of 54 (20.4%) refused to participate and 
43/54 (79.6%) agreed to do so. One patient had to be excluded for other health 
problems (severe cardiac problems) while one further patient decided to undergo 
therapy in a different hospital. Thus, a total of 41 patients completed all 
questionnaires from week 0 to week 6. Thirty-five patients completed 
questionnaires at the time point of 12 weeks, and 34 patients at 30 weeks. Due 
to organisational problems (long distance to our department) these patients were 
lost, because they were followed further on by their urologists. Patient 
characteristics are summarised in Table 2. 
Data analysis 
Scores from SF-36 and EORTC-QLQ-C30 are given as mean SEM. Differences in 
sociodemographic and baseline data between the two groups of patients were 
tested with Chi square tests. Baseline data within each group were tested with 
t-tests for dependent groups against scores at later time points. General linear 
model for repeated measures (GML) with corrections of repeated measures could 
not be performed because sample size was to small.  Association between stage of 
disease, age and precious treatment and quality of life was performed using Chi 
Square tests. Because quality of life data often show a wide interpersonal range 
and the clinical interpretation of small numerical differences is uncertain, we 
included an additional measurement to test the clinical relevance of significant 
results. We used the method described by Osoba et al. (31). Effect sizes were 
calculated to verify significant changes over time: Effect size is calculated by 
dividing the observed differences in mean scores at two different time points by 
the standard deviation of the first time point. 
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Effect size = Mean time point 2 - mean time point 1/SD time point 1. 
An effect size of <0.2 means "no change", effect sizes of 0.2 to 0.5, 0.5 to 
0.8, and > 0.8 indicate little, moderate, and large change, respectively. 
Statistical analysis was done using the Statistical package for the Social 
Sciences (SPSS). 
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Results  
The study population comprised 41 men with a mean age of 67.4 years (range, 50-
84 years). Twenty-two (53.7%) patients received radiotherapy as their primary 
treatment, four (9.7%) were treated following a transurethral resection of the 
prostate gland and fifteen (36.6%) were given radiotherapy following 
prostatectomy. Patients who completed either SF-36 or EORTC QLQ-C 30 did not 
differ in regard of age, stage of disease and treatment plan. 
Five mean values  SEM (baseline to second follow up) of each scale in 
questionnaire SF-36 and questionnaire EORTC QLQ-C 30 are listed in table 3 and 
4, respectively. The scores for the overall quality of life scale in EORTC QLQ-
C30 and the general quality of life/health scale in SF-36 showed no significant 
change during radiotherapy (Fig. 1). At the end of radiotherapy there was a 
significant improvement from baseline (p<0.025) in role functioning due to 
emotional problems (SF-36). No significant change was observed in all other 
scales of SF-36 (physical functioning, social functioning, emotional 
functioning, energy/fatigue, pain and global health). Emotional functioning of 
patients who answered the questionnaire QLQ-C 30 was worst at baseline, improved 
during the first 3 weeks of radiotherapy, but deteriorated again at the end of 
radiotherapy. The score significantly improved 6 weeks after the end of 
radiotherapy, moving from a baseline score of 72 to a mean score of 89 at the 
first follow up (p<0.01). Role functioning (QLQ-C 30) deteriorated during 
radiotherapy from a mean score of 80 before radiotherapy to 62 at the end of 
treatment (p<0.02). Compared with this worst score, role functioning improved 
during the follow-up. Fatigue (QLQ-C 30) worsened as early as at week three of 
radiotherapy and was major determinant with the high score of 37 at the end of 
radiotherapy, but returned to the baseline score shortly after the end of 
radiotherapy (p<0.02). All other scales (physical functioning, social 
functioning, global health/quality of life and pain) remained stable and did not 
appear to be reduced throughout radiotherapy. Chi square tests revealed no 
association between age and stage of disease, or previous treatments to QOL 
(data not given). 
                     Janda et al., page 11 
Since the presented data show high standard deviations as anticipated, 
corrective analysis of significant changes was done by evaluating the effect 
sizes of significant changes. The purpose of this analysis was to determine the 
clinical meaningfulness of the observed significant results. A statistically 
significant increase was registered in the scale "role limitations due to 
emotional problems" in the SF-36. The effect size of this significant change was 
0.56, representing a moderate improvement during the observation period. Three 
statistically significant changes were observed for the patients who answered 
the QLQ-C 30. The effect sizes for these scales resulted in 0.46 for emotional 
functioning, representing a significant but small improvement after 
radiotherapy; 0.55 for role functioning, with a moderate decrease during 
radiotherapy and improvement again during the follow-up period; and 0.53 for 
fatigue, representing a moderate worsening during radiotherapy. 
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Discussion 
The aim of the presented study was to document the quality of life of patients 
suffering from prostate cancer before, during, and at least five months after 
radiotherapy. To our knowledge no longitudinal study with the primary endpoint 
of quality of life for this patient group exists. Therefore the aim of our study 
was to do an exploratory analysis testing the feasibility of quality of life 
questionnaires in this patient population.  Although the number of patients in 
the two groups was small, our results proved that patients had a constant level 
of overall quality of life of approximately 60 from 100 possible points, 
measured with either of the two quality of life questionnaires we used. In 
accordance with the literature, no significant changes in these general QOL 
scales were observed. Radiotherapy did not alter the overall quality of life in 
our patients. Similar results have been reported by cross sectional studies 
assessing the long-term outcome of prostate cancer patients. Using the SF-36, 
Litwin (6) compared the quality of life status of 273 healthy age-matched 
controls with 214 patients treated for prostate cancer. No significant 
differences between patients and controls were found in terms of quality of 
life. Minimal reductions in quality of life have been reported by Shrader-Bogen 
(5) 1 to 5 years after radical prostatectomy, and by Beard (22) 3 to 12 months 
after radiotherapy for prostate cancer. 
Looking at the subscale results, interestingly we found the worst emotional 
status before radiotherapy was started. Emotional wellbeing (QLQ-C30) improved 
moderately at 6 weeks after completion of radiotherapy. Role limitations due to 
emotional problems (SF-36) became significantly and clinically moderately better 
at the end of radiotherapy.  
Patients in several studies (10,24,32,33) have reported feelings of fear and 
anxiety concerning radiotherapy. Patients seem to approach this treatment with 
apprehension. Uncertainty about the course of the disease and fear of the new 
and intimidating therapy may be reasons for the low level of emotional 
functioning at the beginning of radiotherapy. In a recently published study, de 
Graeff and colleagues (34) described a similar pattern of improvement in 
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emotional functioning during radiotherapy in patients treated for laryngeal 
cancer. Rainey demonstrated an anxiety-reducing effect of preparatory 
information groups for radiotherapy patients (32). Reduction of psychological 
distress was shown to have a positive effect on the quality of life (35). 
Role functioning as measured with the QLQ-C30, on the other hand, worsened 
moderately during the treatment. Patients feel disrupted from their normal daily 
activities and responsibilities. The time needed for daily treatment and 
symptoms of fatigue may be the reasons for this result, since role functioning 
recovered 5 months after the end of radiotherapy (21,31). 
Moderate changes in the same direction as for role functioning were seen in the 
fatigue scale of the QLQ-C30. Deterioration of the symptoms of tiredness and 
weakness during radiotherapy was followed by a rapid improvement as early as six 
weeks after the end of treatment. In prostate cancer patients, Greenberg (32) 
found that fatigue initially increased by about 17 fractions and then plateaued. 
Using the Piper Fatigue Scale, Monga (21) registered a significant increase in 
fatigue at the completion of radiotherapy in comparison with the baseline score. 
The high fatigue levels in these patients (21) were reduced 5 weeks after the 
end of treatment but, in contrast to our results, did not reach baseline levels. 
Fossa (7) found fatigue to be a general problem among men in different treatment 
groups (watchful waiting, hormonal, radiotherapy, prostatectomy) with highest 
fatigue levels in the radiotherapy and hormone group. The author claims that 
physicians often underestimate the impact of fatigue on the wellbeing of 
prostate cancer patients. 
In contrast to a recently published paper (16), we did not ask our patients to 
fill in both QOL questionnaires during the same session. Therefore it was not 
possible to directly compare the results of the two questionnaires, because the 
scales of the two questionnaires were developed under different conceptual 
frameworks and for different patient samples. However, looking at the results of 
the QLQ-C 30 and the SF-36, it may be concluded that the QLQ-C30 permitted 
registration of significant changes within three subscales (emotional 
functioning, role functioning and fatigue) whereas the SF-36 measured 
significant changes within one scale (role limitations due to emotional 
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functioning) only. Statements of the patients during testing suggested that the 
QLQ-C30 was well tolerated by the patients and covered their feelings well. This 
was not true to the same extent for the SF-36. 
 
In summary, our study proved that radiotherapy did not affect general quality of 
life but had a temporal effect on fatigue, role functioning and emotional 
wellbeing. Supportive and educational groups might have a stabilising effect on 
the emotionality of prostate cancer patients before radiotherapy is started. 
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Table 1. Subscales that are represented in SF-36 (Medical Outcomes Study Group Short Form Health Survey) and EORTC QLQ-
C30  (European Organization for Research and Treatment Quality of Life Questionnaire) and were used for analysis 
 SF-36 EORTC QLQ-C 30                  
Characteristics Aspect, Domain No. of items Aspect, Domain No. of items 
Complete 
Questionnaire 
 36  30 
Subscales  Physical functioning 10 Physical functioning 5 
 Social functioning 2 Social functioning  2 
 Emotional functioning 5 Emotional functioning  4 
 Role limitations due to 
emotional functioning 
3 Role functioning 4 
 Energy/fatigue 4 Fatigue 3 
 Pain 2 Pain 2 
 General health 5 General health/quality of life 3 
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Table 1 continued 
 SF-36  EORTC QLQ-C 30  
Characteristics Aspect, Domain No. of items Aspect, Domain No. of items 
Type of response 
scale 
Some dichotomous items, most 
items on 3 to 6 ordinal scale, 
Likert type 
 5 point ordinal scale, Likert 
type 
 
Time frame Past four weeks  Past week  
Results  Transformed to 0-100 score, 
with higher scores 
representing better QL 
 Transformed to 0-100 score, 
with higher scores 
representing better QL, except 
for the symptom scales, with 
higher scores representing 
higher symptoms 
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Table 2: Patient characteristics 
Questionnaire SF-36 QLQ-C 30 P 
Number of patients 20 21  
Mean age 67.0 67.7 0.3 
T stage   0.64 
T2 N0 10 (50.0%) 12 (57.1%)  
T3 N0 9 (45.0%) 8 (38.1%)  
T3 N1 1 (5.0%) 1 (4.8%)  
Treatment   0.48 
Primary radiotherapy 12 (60.0%) 10 (47.6%)  
Radiotherapy following TURP 1 (5.0%) 3 (14.3%)  
Radiotherapy following RPE 7 (35.0%) 8 (38.1%)  
Abbreviations: SF-36 - Medical Outcomes Study Group Short Form Health Survey; EORTC-QlQ-C30 - European Organization 
for Research and Treatment Quality of Life Questionnaire; TURP - transurethral prostatectomy; RPE - radical 
prostatectomy. 
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Table 3. Quality of life score deriving from SF-36 
SF-36 0 we  3 we  6 we 12 we  30 we 
Physical functioning 82.3 (4.2) 81.4 (4.4) 83.7 (4.0) 84.0 (2.9) 82.3 (3.9) 
Social functioning 82.8 (6.2) 82.8 (4.7) 80.6 (4.5) 88.1  (4.6) 86.9 (3.8) 
Emotional functioning  78.1 (3.2) 81.9 (2.8) 81.4 (4.0) 74.3 (4.7) 79.2 (3.9) 
Role limitations due to emotional problems 68.2 (9.9) 82.5 (5.9) 93.3 (5.2)* 82.4 (8.2) 88.2 (6.9) 
Energy/fatigue  64.7 (4.2) 65.9 (3.7) 66.2 (4.8) 60.5 (4.5) 66.1 (2.9) 
Pain  84.4 (4.0) 91.0 (3.2) 85.2 (5.1) 84.4 (5.0) 92.2 (4.4) 
General Health 57.6 (4.5) 56.4 (3.9) 58.2 (4.2) 58.9 (4.2) 56.7 (4.4) 
Data are presented as means (±SEM). Scores can range from 0-100, higher scores representing better quality of life. 
Abbreviations: SF-36 - Medical Outcomes Study Group Short Form Health Survey; 0we - baseline, 3we - in the middle, and 
6we - at the end of radiotherapy respectively, 12we - 12 weeks after baseline, 30we - 30 weeks after baseline 
*p<0.02, paired t-test evaluating the rate of change from pretreatment scores. 
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Table 4. Quality of life score deriving from EORTC-QLQ C30 
EORTC QLQ C-30 0 we 3 we 6 we 12 we 30 we 
Physical functioning 82.3 (5.5) 79.0 (7.6) 78.0 (6.8) 80.0 (7.5) 78.2 (8.2) 
Social functioning 77.7 (7.0) 77.5 (6.6) 75.0 (7.9) 90.6 (6.4) 94.1 (3.5) 
Emotional functioning 72.7 (5.9) 83.0 (3.6) 73.3 (7.6) 89.0 (4.4)* 85.7 (3.9) 
Role functioning 80.1 (6.5) 75.0 (6.7) 62.5 (8.8)* 76.0 (9.2) 84.3 (6.9) 
General Health/QOL  60.3 (5.5) 66.2 (5.4) 58.3 (5.6) 68.2 (7.1) 62.2 (6.9) 
Fatigue # 26.9 (6.0) 30.5 (7.2) 37.7 (7.6)* 22.2 (8.1) 22.2 (7.6) 
Pain # 13.4 (5.7) 7.5 (3.3) 12.5 (5.1) 17.7 (6.5) 16.6 (6.4) 
 
Data are presented as means (±SEM). Scores ranging from 0-100, with higher scores representing higher quality of 
life. 
Abbreviations: EORTC-QlQ-C30 - European Organization for Research and Treatment Quality of Life Questionnaire; 0we - 
baseline, 3we - in the middle, and 6we - at the end of radiotherapy respectively, 12we - 12 weeks after baseline, 
30we - 30 weeks after baseline 
#A high score reflects a high level of symptoms in these two scales. 
*p<0.02, paired t-test evaluating the rate of change from pretreatment scores. 
